

Obizur [Antihemophilic Factor (Recombinant), Porcine Sequence]

PLEASE JOIN US FOR A
LIVE PROGRAM FOR:

OBIZUR®: A FIRST-LINE TREATMENT OPTION FOR ACQUIRED HEMOPHILIA A

Program Objectives

- Review the clinical features, diagnosis, and management of acquired hemophilia A (AHA)
- Share the clinical study data (efficacy and safety) supporting the indication of OBIZUR for treatment of bleeding episodes in adults with AHA
- Discuss patient cases in which OBIZUR may be appropriate

PRESENTER

Sandeep Rajan, MBBS,MD

University of Tennessee Health Science Center

UCH Hematology

Memphis, TN

PROGRAM INFORMATION

Date Tuesday, February 11, 2020

Time 6:30PM

Venue

The Palm

233 E Houston Street

San Antonio, TX 78205

REGISTRATION INFORMATION

RSVP by

Friday, February 7, 2020

Register online at

<http://www.programrsvp.com/HEM-1622>

Or please contact your local Takeda representative

Aaron Consuelo

aaron.consuelo@shire.com

Indications

OBIZUR, Antihemophilic Factor (Recombinant), Porcine Sequence, is a recombinant DNA derived, antihemophilic factor indicated for the treatment of bleeding episodes in adults with acquired hemophilia A.

Limitations of Use:

- Safety and efficacy of OBIZUR has not been established in patients with baseline anti-porcine factor VIII inhibitor titer greater than 20 BU
 - OBIZUR is not indicated for the treatment of congenital hemophilia A or von Willebrand disease
- OBIZUR is contraindicated in patients who have had life-threatening hypersensitivity reactions to OBIZUR or its components (including traces of hamster proteins).

Please see OBIZUR Detailed Risk Information on the following page.

Please [click here](#) for OBIZUR full Prescribing Information.



OBIZUR® (Antihemophilic Factor [Recombinant], Porcine Sequence) INDICATIONS AND DETAILED IMPORTANT RISK INFORMATION

Indication

OBIZUR, Antihemophilic Factor (Recombinant), Porcine Sequence, is a recombinant DNA derived, antihemophilic factor indicated for the treatment of bleeding episodes in adults with acquired hemophilia A.

Limitations of Use:

- Safety and efficacy of OBIZUR has not been established in patients with baseline anti-porcine factor VIII inhibitor titer greater than 20 BU
- OBIZUR is not indicated for the treatment of congenital hemophilia A or von Willebrand disease

Detailed Important Risk Information

CONTRAINDICATIONS

OBIZUR is contraindicated in patients who have had life-threatening hypersensitivity reactions to OBIZUR or its components (including traces of hamster proteins).

WARNINGS AND PRECAUTIONS

Hypersensitivity Reactions

Hypersensitivity reactions can occur with OBIZUR. OBIZUR contains trace amounts of hamster proteins. Early signs of allergic reactions, which can progress to anaphylaxis, include angioedema, chest-tightness, dyspnea, hypotension, wheezing, urticaria, and pruritus. Immediately discontinue administration and initiate appropriate treatment if allergic or anaphylactic-type reactions occur.

Inhibitory Antibodies

Inhibitory antibodies to OBIZUR have occurred. Monitor patients for the development of antibodies to OBIZUR by appropriate assays. If the plasma factor VIII level fails to increase as expected, or if bleeding is not controlled after OBIZUR administration, suspect the presence of an anti-porcine factor VIII antibody. If such inhibitory antibodies to anti-porcine factor VIII are suspected and there is a lack of clinical response, consider other therapeutic options.

Monitoring Laboratory Tests

- Perform one-stage clotting assay to confirm that adequate factor VIII levels have been achieved and maintained
 - Monitor factor VIII activity 30 minutes and 3 hours after initial dose
 - Monitor factor VIII activity 30 minutes after subsequent doses
- Monitor the development of inhibitory antibodies to OBIZUR. Perform a Nijmegen Bethesda inhibitor assay if expected plasma factor VIII activity levels are not attained or if bleeding is not controlled with the expected dose of OBIZUR. Use Bethesda Units (BU) to report inhibitor levels

ADVERSE REACTIONS

Common adverse reactions observed in greater than 5% of subjects in the clinical trial were development of inhibitors to porcine factor VIII.

Please [click here](#) for OBIZUR full Prescribing Information.

This is a non-CME program sponsored by Takeda Pharmaceutical Company Limited. Takeda is prohibited from providing meals to prescribers that are licensed by the State of Minnesota and healthcare professionals that are licensed by the State of Vermont. Prescribers licensed by the State of NJ may not consume a Takeda-offered meal in excess of \$15. Invitees cannot bring guests. Takeda will collect and report healthcare professional information concerning meals and other transfers of value pursuant to the Federal Sunshine Act and state laws.

Obizur
[Antihemophilic Factor
(Recombinant), Porcine Sequence]

